Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression Six-Month Patient Follow-up Results Demonstrate that Sana’s Transplanted Pancreatic Islet Cells Modified with its Hypoimmune (HIP) Technology are Safe and Well-tolerated, Survive, Evade Detection by the Immune System, and Continue to Produce Insulin in the Patient Function and Persistence of Pancreatic Islets Were Detectable by Production of Consistent Levels ...

Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetesSEATTLE, June 09, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced an upcoming podium presentation highlighting ongoing clinical data from the investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cel ...

Core Insights - Sana Biotechnology, Inc. has made significant progress in developing therapies for type 1 diabetes, with promising clinical results indicating that hypoimmune-modified pancreatic islet cells can function without immunosuppression and maintain stable C-peptide production post-transplant [1][2][5] - The company is advancing its pipeline with ongoing trials for SC291 and SC262 targeting B-cell mediated autoimmune diseases and relapsed/refractory B-cell malignancies, respectively, with data expected in 2025 [1][7] - Financially, Sana reported a cash position of $104.7 million as of Q1 2025, with a cash runway expected to extend into 2026 [1][6] Clinical Developments - The ongoing UP421 trial has shown that hypoimmune-modified pancreatic islets can evade immune detection and continue to function three months post-transplant, which is a critical step towards a functional cure for type 1 diabetes [2][5] - Preclinical data for SC451 demonstrated 15-month durability of glycemic control in a mouse model, with no histological abnormalities, supporting its potential for future clinical application [4] - The GLEAM and VIVID trials are currently enrolling patients, with expectations to report clinical data in 2025 [1][7] Financial Performance - For Q1 2025, the company reported a net loss of $49.4 million, or $0.21 per share, a significant reduction from a net loss of $107.5 million, or $0.49 per share, in Q1 2024 [6][14] - Research and development expenses decreased to $37.2 million in Q1 2025 from $56.4 million in the same period in 2024, primarily due to lower personnel-related and clinical development costs [6][14] - The company’s non-GAAP operating cash burn for Q1 2025 was $46.6 million, down from $58.7 million in Q1 2024, indicating improved cash management [10][19]